# Immunovant, Inc.: Form 8-K, filed Feb 4, 2022

- Company: [Immunovant, Inc.](/companies/imvt.md) (CIK 1764013)
- Form: 8-K
- Filed: 2022-02-04
- Accepted by EDGAR: Feb 4, 2022, 07:09 ET
- Period: 2022-02-04
- Accession: 0001764013-22-000029
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000029/imvt-20220204.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000029/

## Items reported

- Item 2.02: Results of operations
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1764013/000176401322000029/imvt-20220204.htm

Filed Feb 4, 2022.
Source: SEC EDGAR, the filing index for accession 0001764013-22-000029. Last ingested by Listed: Nov 13, 2026, 16:26 ET. No prices; not investment advice.
